Manuel Barreiro-de Acosta Selected Research

Therapeutics

8/2022	Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU.
1/2022	Corrigendum to: Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
1/2022	COVID-19-related personal product shortages are associated with psychological distress in people living with gastrointestinal disorders: A cross-sectional survey.
1/2022	Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.
1/2022	Usefulness of peripheral blood monocyte count to predict relapse in patients with inflammatory bowel disease: a prospective longitudinal cohort study.
1/2022	Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
1/2021	Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.
12/2020	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment.
2/2020	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis.
1/2020	Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Manuel Barreiro-de Acosta Research Topics

Disease

33	Crohn Disease (Crohn's Disease) 11/2022 - 01/2007
28	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 12/2022 - 09/2011
24	Ulcerative Colitis 05/2022 - 08/2009
7	Necrosis 01/2021 - 01/2015
4	Pouchitis 12/2020 - 07/2012
3	Latent Tuberculosis 01/2021 - 07/2017
3	Colitis 01/2019 - 07/2010
2	Fistula 08/2022 - 01/2015
2	COVID-19 01/2022 - 01/2022
1	Spontaneous Abortion (Miscarriage) 09/2022
1	Stillbirth 09/2022
1	Hypersensitivity (Allergy) 07/2022
1	Psoriasis (Pustulosis Palmaris et Plantaris) 07/2022
1	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 05/2022
1	Pain (Aches) 01/2022
1	Psoriatic Arthritis 01/2021
1	Inflammation (Inflammations) 01/2021
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2021
1	Tuberculosis (Tuberculoses) 01/2021
1	Infections 11/2020
1	Hepatitis B 11/2020
1	Myocardial Infarction 01/2020
1	Skin Diseases (Skin Disease) 01/2020
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2020
1	Disease Progression 10/2018
1	Iron-Deficiency Anemia (Anemia, Iron Deficiency) 03/2018
1	Colorectal Neoplasms (Colorectal Cancer) 03/2016
1	Anemia 10/2013
1	Iron Deficiencies 10/2013
1	Microscopic Colitis 04/2013
1	Drug-Related Side Effects and Adverse Reactions 09/2011

Drug/Important Bio-Agent (IBA)

12	Infliximab (Remicade)FDA Link 07/2022 - 08/2009
10	Biological ProductsIBA 01/2022 - 07/2010
10	Adalimumab (Humira)FDA Link 01/2019 - 08/2009
7	Pharmaceutical PreparationsIBA 07/2022 - 12/2011
7	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 03/2013
6	Ustekinumab (CNTO 1275)FDA Link 11/2022 - 01/2020
5	Biomarkers (Surrogate Marker)IBA 03/2022 - 01/2015
5	SteroidsIBA 07/2017 - 01/2007
4	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020 - 12/2009
4	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2019 - 01/2016
3	vedolizumabIBA 06/2021 - 12/2019
3	2-mercaptopurineIBA 03/2016 - 04/2013
2	Anti-Bacterial Agents (Antibiotics)IBA 12/2020 - 01/2020
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2019 - 07/2017
2	Tuberculin (PPD)IBA 11/2018 - 07/2017
2	Ferritins (Ferritin)IBA 03/2018 - 10/2013
2	Beclomethasone (Beclometasone)FDA Link 04/2013 - 12/2010
1	VaccinesIBA 12/2022
1	COVID-19 VaccinesIBA 12/2022
1	RadonIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Tumor Necrosis FactorsIBA 06/2021
1	Biosimilar PharmaceuticalsIBA 03/2021
1	tofacitinibIBA 01/2021
1	CreatinineIBA 01/2021
1	HomoserineIBA 01/2021
1	Immunologic Factors (Immunomodulators)IBA 01/2021
1	Methionine (L-Methionine)FDA Link 01/2021
1	Proline (L-Proline)FDA Link 01/2021
1	Essential Amino AcidsIBA 01/2021
1	CreatineIBA 01/2021
1	Tryptophan (L-Tryptophan)FDA Link 01/2021
1	Immunomodulating AgentsIBA 01/2021
1	FendrixIBA 11/2020
1	Engerix-BIBA 11/2020
1	AntibodiesIBA 12/2019
1	IntegrinsIBA 12/2019
1	Monoclonal AntibodiesIBA 12/2019
1	AcidsIBA 10/2018
1	Hemoglobins (Hemoglobin)IBA 03/2018
1	golimumab FDA Link 01/2017
1	P-2 (P 2)IBA 04/2015
1	Transferrin (beta 2 Transferrin)IBA 10/2013
1	Budesonide (Pulmicort)FDA LinkGeneric 04/2013
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 12/2011
1	Methotrexate (Mexate)FDA LinkGeneric 10/2011
1	Azathioprine (Imuran)FDA LinkGeneric 09/2011
1	EnzymesIBA 09/2011

Therapy/Procedure

32	Therapeutics 08/2022 - 12/2009
3	Restorative Proctocolectomy 05/2022 - 11/2019
3	Biological Therapy 01/2022 - 08/2009
3	Blood Component Removal (Apheresis) 12/2019 - 08/2018
2	Complementary Therapies (Alternative Medicine) 01/2019 - 11/2012
1	Cesarean Section (Caesarean Section) 09/2022
1	Colonic Pouches (S Pouch) 05/2022
1	Operative Surgical Procedures 05/2022
1	Bathroom Equipment 01/2022
1	Precision Medicine 12/2021
1	Chemoprevention 01/2021
1	Drug Therapy (Chemotherapy) 04/2013